SCIENTIFIC RESULTS

PN6047 CONCISELY

Therapeutic focus » Scientific Results

Neuropathic pain therapy point by point

OUR LEAD MOLECULE PN6047 has the ability to become a medicine for the treatment of chronic pain. This is underpinned by the following:

  • PN6047 is a novel fully patented molecule without any significant toxic effects in preclinical testing. PN6047 can be cost effectively synthesized
  • PN6047 is highly selective for the delta opioid receptor and does not interact with other receptors, transporters or enzymes studied
  • PN6047 preferentially signals via Gi proteins compared with arrestin proteins
  • PN6047 has high potency and efficacy in reducing neuropathic pain in various animal models
  • PN6047 lacks unwanted morphine-like side-effects, such as analgesic tolerance, drug abuse potential and respiratory depression
  • PN6047 has an excellent preclinical safety profile lacking CVS/GIT interactions and seizure induction
  • PN6047 shows no histopathological  effects following long-term multiple high dose administration.

THUS, PN6047 can be the drug of choice to combat neuropathic pain and other conditions involving sensory hypersensitivity such as chronic cough and itch.

PN6047 versus conventional

The advantages of PN6047, versus current neuropathic pain medicines are potentially substantial.

vs Conventional Opioids:  
Better efficacy in sensory hypersensitivity disorders; no μ-opioids receptor side effects; no analgesic  tolerance; no abuse potential.

vs Gabapentin:
No dose adjustment in renal insufficiency patients; no abuse potential; no cytochrome enzyme inhibition so less drug interactions.

vs Amitriptyline:
No cardiovascular complications; lower metabolite exposure; no dose adjustment in hepatic insufficiency patients; no significant food or drug interactions.

Latest news

View all
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more
October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

Read more
September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

Read more
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more